Cardiopulmonary bypass in malignant hyperthermia susceptible patients: A systematic review of published cases

被引:14
|
作者
Metterlein, Thomas [1 ]
Zink, Wolfgang [1 ]
Kranke, Eva [3 ]
Haneya, Assad [2 ]
Graf, Bernhard [1 ]
Kranke, Peter [4 ]
机构
[1] Univ Hosp Regensburg, Dept Anesthesiol, D-93051 Regensburg, Germany
[2] Univ Hosp Regensburg, Dept Cardiosurg, D-93051 Regensburg, Germany
[3] Univ Hosp Wurzburg, Dept Cardiosurg, Wurzburg, Germany
[4] Univ Hosp Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany
来源
关键词
CORONARY-ARTERY-BYPASS; SKELETAL-MUSCLE PREPARATIONS; MITRAL-VALVE-REPLACEMENT; CENTRAL CORE DISEASE; CARDIAC-SURGERY; DANTROLENE; RHABDOMYOLYSIS; DIAGNOSIS; MANAGEMENT; SWINE;
D O I
10.1016/j.jtcvs.2011.01.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Malignant hyperthermia susceptibility is an important risk factor during general anesthesia. Affected patients have an asymptomatic but potentially lethal hypermetabolic reaction after contact with volatile anesthetics or succinylcholine. Classic symptoms include hemodynamic instability, combined with acidosis, rigor, and hyperthermia. During cardiopulmonary bypass, these signs may be obscured, delaying correct diagnosis and lifesaving treatment. Malignant hyperthermia-susceptible individuals are more sensitive to heat and stress, so rewarming and catecholamine administration may trigger an episode, necessitating prophylactic measures. Methods: This systematic review identified typical malignant hyperthermia symptoms during cardiopulmonary bypass and investigated other factors in cardiac surgery that might trigger an episode in susceptible individuals. Approaches used to treat and prevent malignant hyperthermia during cardiopulmonary bypass were systematically analyzed. We conducted a systematic search for reports about malignant hyperthermia and cardiopulmonary bypass. Search terms included malignant hyperthermia and cardiopulmonary bypass, extracorporeal circulation, or cardiac surgery. Results: We found 24 case reports and case series including details of 26 patients. In 14 cases, malignant hyperthermia crises during or shortly after cardiopulmonary bypass were described. Fourteen reports discussed prevention of an episode. Early symptoms of a malignant hyperthermia episode include excessive carbon dioxide production and metabolic acidosis. Massively increased creatine kinase levels are a strong indicator of a malignant hyperthermia reaction. Rewarming is associated with development of clinical signs of malignant hyperthermia. Conclusions: In potentially susceptible patients, apart from avoiding classic trigger substances, aggressive rewarming should not be applied. Hemodynamic instability in conjunction with the described symptoms should result in a diagnostic algorithm. (J Thorac Cardiovasc Surg 2011;141:1488-95)
引用
收藏
页码:1488 / 1495
页数:8
相关论文
共 50 条
  • [1] MALIGNANT HYPERTHERMIA - A REVIEW OF PUBLISHED CASES
    STRAZIS, KP
    FOX, AW
    ANESTHESIA AND ANALGESIA, 1993, 77 (02): : 297 - 304
  • [2] Successful Management of Hypothermic Cardiopulmonary Bypass in a Malignant Hyperthermia Susceptible Patient
    Agarwal, Shvetank
    Graham, Kevin
    Kigwana, Simon
    Castresana, Manuel
    ANNALS OF CARDIAC ANAESTHESIA, 2020, 23 (03) : 367 - 371
  • [3] Can we prevent malignant hyperthermia after hypothermic cardiopulmonary bypass in a malignant hyperthermia-susceptible patient?
    Siddik-Sayyid, Sahar M.
    Moussa, Adib R.
    Baraka, Anis S.
    ANESTHESIA AND ANALGESIA, 2007, 104 (01): : 214 - 214
  • [4] Rhabdomyolysis following cardiopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia
    Riess, FC
    Fiege, M
    Moshar, S
    Bergmann, H
    Bleese, N
    Kormann, J
    Weisshorn, R
    Wappler, F
    ANESTHESIOLOGY, 2001, 94 (02) : 355 - 357
  • [5] CARDIOPULMONARY BYPASS IN TREATMENT OF MALIGNANT HYPERTHERMIA
    RYAN, JF
    DONLON, JV
    MALT, RA
    BLAND, JHL
    BUCKLEY, MJ
    SRETER, FA
    LOWENSTEIN, E
    NEW ENGLAND JOURNAL OF MEDICINE, 1974, 290 (20): : 1121 - 1122
  • [6] Use of Cardiopulmonary Bypass for Treatment of Malignant Hyperthermia
    Phillips, Thomas
    Zimmermann, Eric
    Dukatz, Chris
    Tully, Michelle
    Aziken, Nkem
    Raman, Jaishankar
    Merkel, Matthias
    Sera, Valerie
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2020, 34 (03) : 753 - 755
  • [7] Development of malignant hyperthermia during cardiopulmonary bypass
    Lindholm, P
    Andersen, S
    Andersen, C
    Fisker, J
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2000, 14 (05) : 576 - 578
  • [8] THE OCCURRENCE OF MALIGNANT HYPERTHERMIA DURING CARDIOPULMONARY BYPASS
    KEMNA, GD
    GERVAIS, BM
    BROWNLEE, RT
    PROCEEDINGS OF THE AMERICAN ACADEMY OF CARDIOVASCULAR PERFUSION, VOL 9, 1988, 9 : 165 - 167
  • [9] DEVELOPMENT OF MALIGNANT HYPERTHERMIA OBSCURED BY CARDIOPULMONARY BYPASS
    MACGILLIVRAY, RG
    JANN, H
    VANKER, E
    MAHOMEDY, AE
    CANADIAN ANAESTHETISTS SOCIETY JOURNAL, 1986, 33 (04) : 509 - 514
  • [10] Systematic Review of Succinylcholine Induced Cases of Malignant Hyperthermia
    Atkins, Alexandra
    Driver, Brian
    Cole, Jon
    CLINICAL TOXICOLOGY, 2019, 57 (10) : 887 - 887